The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026
Harbour BioMed brings advanced antibody discovery platforms to the table
CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development
The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas
The partnership also sets the stage for broader collaboration on rare disease treatments
TMS offers new hope to patients suffering from stroke, migraine, neuropathic pain, depression, and other disorders
The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38
The cancellation underscores the regulator’s strict stance against misleading cosmetic claims
Lupin has bolstered its diabetes and obesity portfolios by securing an agreement for Bofanglutide, a GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals
The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy
Subscribe To Our Newsletter & Stay Updated
